IMMX · Why this verdict
Why Immix Biopharma (IMMX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Immix Biopharma is a pre-revenue, cash-burning biotech whose value rests on a single pipeline asset (NXC-201) and an analyst target far above the current $8.15 price, but weak quality and deteriorating momentum limit conviction.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's prospects hinge on one pipeline asset, NXC-201, manufactured by third-party CMOs, so a setback in either would impair the whole thesis. Bear case | NXC-201 advances without manufacturing or supply disruption over the next 12 months. | ↑Improving |
| CounterSingle-asset biotechs routinely fail on one trial readout or supplier problem, and nothing in the data shows diversification. | ||
Quality is weak at 1.6/10 with negative free cash flow, no competitive moat, and zero reported revenue across the last five quarters. Quality breakdown | Cash burn stays funded and quarterly losses per share do not widen beyond the recent -$0.18. | →Stable |
| CounterWithout revenue, funding depends on capital raises that could dilute shareholders at lower prices. | ||
Analysts' target of $21.25 implies 160.7% upside from $8.15, versus a 13.7% downside to the $7.64 stop, a reward-to-risk of 11.7. Targets | Price moves toward the analyst target as clinical milestones are delivered. | ↓Deteriorating |
| CounterLight analyst coverage dampens the signal, and targets for speculative biotechs are often cut after trial news. | ||
Momentum is poor at 2.3/10 with RSI 28, falling on-balance volume and price below the 200-day average, though that average is still rising. Momentum breakdown | Price stabilizes above the 200-day moving average and on-balance volume stops falling. | ↑Improving |
| CounterCapitulation selling and 15% short interest can push the stock down further before any recovery. | ||
Earnings results are mixed: 2 misses and 1 beat in the last 4 quarters, with an average surprise of -22.6%, and the next report is due in 13 days. Earnings | Quarterly loss per share lands at or better than estimates for the next several reports. | ↑Improving |
| CounterLosses at a pre-revenue biotech are lumpy and EPS surprises say little about clinical value. | ||
The company's prospects hinge on one pipeline asset, NXC-201, manufactured by third-party CMOs, so a setback in either would impair the whole thesis.
↑ImprovingBear case
- Expectation
- NXC-201 advances without manufacturing or supply disruption over the next 12 months.
CounterSingle-asset biotechs routinely fail on one trial readout or supplier problem, and nothing in the data shows diversification.
Quality is weak at 1.6/10 with negative free cash flow, no competitive moat, and zero reported revenue across the last five quarters.
→StableQuality breakdown
- Expectation
- Cash burn stays funded and quarterly losses per share do not widen beyond the recent -$0.18.
CounterWithout revenue, funding depends on capital raises that could dilute shareholders at lower prices.
Analysts' target of $21.25 implies 160.7% upside from $8.15, versus a 13.7% downside to the $7.64 stop, a reward-to-risk of 11.7.
↓DeterioratingTargets
- Expectation
- Price moves toward the analyst target as clinical milestones are delivered.
CounterLight analyst coverage dampens the signal, and targets for speculative biotechs are often cut after trial news.
Momentum is poor at 2.3/10 with RSI 28, falling on-balance volume and price below the 200-day average, though that average is still rising.
↑ImprovingMomentum breakdown
- Expectation
- Price stabilizes above the 200-day moving average and on-balance volume stops falling.
CounterCapitulation selling and 15% short interest can push the stock down further before any recovery.
Earnings results are mixed: 2 misses and 1 beat in the last 4 quarters, with an average surprise of -22.6%, and the next report is due in 13 days.
↑ImprovingEarnings
- Expectation
- Quarterly loss per share lands at or better than estimates for the next several reports.
CounterLosses at a pre-revenue biotech are lumpy and EPS surprises say little about clinical value.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 6.6 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 2.8 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+7.5%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
8.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.9 |
| Price target | 10.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 201%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.8 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.6 |
| support resistance | 9.0 |
| 52w position | 0.8 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.0 |
| days to cover | 4.2 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 10.0 |
| debt equity | 10.0 |
- ▸High short interest justified: 15%
- ▸High IV: 101%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/2M
- ▸Earnings in 8 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (4)
- INSIDER:OK
- 8K:CLEAN
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.2<4.5
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- EARNINGS_PROXIMITY:8d<=14d (soft)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
12.8%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -46% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.2<4.5 outcome against Sentiment at 8.1 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 8.1, Insider at 7.3, and Peer rank at 5.9; the weakest are Quality at 1.6, Catalyst at 3.2, and Momentum at 3.2. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Concentration
Trip ifA clinical hold or supply disruption delays NXC-201 by more than 2 quarters.
- P2Cash Burning No Revenue
Trip ifQuarterly loss per share widens to more than $0.28 for 2 consecutive quarters.
- P3Analyst Target Upside
Trip ifAverage analyst target falls below $12.00 from the current $21.25.
- P4Weak Momentum Capitulation Risk
Trip ifMomentum score stays below 2.0 for 2 consecutive months.
- P5Inconsistent Earnings Execution
Trip ifEPS surprise stays below -25% for 2 consecutive quarters.